CN1245057A - Reversing agent for multi-medicine resistance of tumor cells - Google Patents
Reversing agent for multi-medicine resistance of tumor cells Download PDFInfo
- Publication number
- CN1245057A CN1245057A CN 98117402 CN98117402A CN1245057A CN 1245057 A CN1245057 A CN 1245057A CN 98117402 CN98117402 CN 98117402 CN 98117402 A CN98117402 A CN 98117402A CN 1245057 A CN1245057 A CN 1245057A
- Authority
- CN
- China
- Prior art keywords
- compound
- tumor
- resistance
- acid
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A reversing agent for the multi-drug resistance of tumor cells is the isosteroid alkaloid derivatives extracted from tendrilled fritillary bulb. It can also be applied in conjuction with other medicines for higher reversing effect.
Description
The invention belongs to the new purposes of plant compound field.This invention relates to a kind of new multidrug resistance tumor cells inversion agent.They are different steroid alkaloid derivants that separation and Extraction obtains from plant such as liliaceous plant Bulbus Fritillariae Uninbracteatae.
The chemical anticarcinogenic drug treatment occupies critical role in clinical therapy of tumor, but the tumor cell drug resistance problem but is chemotherapeutical huge obstacle.In a sense, it is all relevant with former of tumor or acquired resistance to die from the case of tumor more than 90%.Begin the seventies with regard to the multidrug resistance problem of noticing tumor cell the influence of clinical Combination chemotherapy greatly (oncology clinical with advances of Basic Research work Atomic Energy Press front page in 1994 such as Sun Yan P.245).For this reason, actively develop the research of tumor cell drug resistance inversion agent both at home and abroad.Found the inversion agent that multiple effect is higher in the laboratory at present, as the calcium ion antagonist isoptin, immunosuppressant cyclosporin A or the like.But because problem such as toxic and side effects, does not still have so far generally acknowledge can the medicine of clinical widespread usage (Chinese Journal of Hematology 1990,3 (2): 161, treatment and prevention of tumour studies 1995,1 (22): 61, practical tumor magazine 1995,4 (10): 204).As mentioned above, current clinical this class medicine that presses for.
First purpose of the present invention provides the novel tumor multidrug-resistance inversion agent of a class.
Second purpose of the present invention provides different steroid alkaloid as the purposes of multidrug resistance tumor cells inversion agent in treatment multidrug resistance tumor disease.
Further object of the present invention provides a kind of pharmaceutical composition that has good reverse effect for tumor multidrug-resistance.
Purpose according to the present invention, the tumor multidrug-resistance inversion agent that is provided are different steroid alkaloid derivants.This chemical compound mainly is from plant, can be from common Chinese medicine such as liliaceous plant Bulbus Fritillariae Uninbracteatae separation and Extraction.It can make tumor multidrug-resistance greatly lower.
This chemical compound has following structure:
R wherein
1Can be
Or H R
2Can be
Or=O
R
3, R
4, R
5Can be H, R
6Can be OH
According to the present invention, different steroid alkaloid derivant can be made into the preparation of intestinal or non-intestinal combination medicine by means known in the art.As tablet, capsule, granule, injection etc.
According to the present invention, different steroid alkaloid derivant also can with other inversion agent 5 usefulness, reach the purpose that improves reverse effect.As improving nearly twenty times of reverse effect by 1: 15 time spent with isoptin.
Useful effect: chemical compound of the present invention has potential applicability in clinical practice, because if when giving dose corresponding to Bulbus Fritillariae Uninbracteatae dosage clinically, be unlikely obvious toxic and side effects, and this chemical compound can make tumor multidrug-resistance greatly lower, can reach about five times.As with isoptin (clinical commonly used drug) 5 usefulness, effect still can greatly improve.The prospect that indicates this compounds clinical practice is better.The drug resistance of tumor problem is chemotherapeutical huge obstacle.The case of dying from tumor is all relevant with former of tumor or acquired resistance.So current clinical this class reversing drug that presses for is used for the treatment of the multidrug-resistant carcinoma disease.
The following examples will describe the present invention in detail.The extraction of embodiment 1 different steroid alkaloid derivant and structure are identified:
Chemical compound of the present invention can extract from plant such as liliaceous plant Bulbus Fritillariae Uninbracteatae and obtain.Its concrete preparation route is as follows:
Get Bulbus Fritillariae Thunbergii decoction pieces 9kg, add 95% ethanol, reflux, extract.Medicinal residues are added with 95% ethanol, reflux, extract.Discard medicinal residues.Merge alcohol extract.Decompression recycling ethanol gets alcohol extract.Alcohol extract stirs molten with 2～3% hydrochloric acid, the filtering insoluble matter.Acid liquid is transferred PH to 10 with sodium hydroxide, extracts with chloroform.Tell the chloroform layer.Reclaim solvent, get total alkaloids 16.5g.Total alkaloids is through silica gel column chromatography, and chloroform-methanol system gradient elution gets chemical compound first 0.78g, chemical compound second 0.65g, chemical compound third 0.66g, chemical compound fourth 0.84g, chemical compound penta 0.12g according to this.Through identifying:
The chemical compound first is colourless acicular crystal mp214～215 ℃ .EL-MSm/z:429.3 (M
+), 411.3,384.3,155.1,154.1,112.1 (100%), 98.1,69.1.
1HNMR δ ppm (CD
3OD, 400MHz): 0.76 (3H, S, H-19), 1.05 (3H, S, H-21), 1.11 (3H, d, J=7.33Hz, H-27), 3.51 (1H, m, W
1/2=18.6Hz, H-3).
13The CNMR data see the following form.Itself and peimine standard substance mixed melting point do not descend, altogether thin layer Rf unanimity.
Chemical compound second is colourless acicular crystal, mp222-224 ℃.
1HNMR ﹠amp; Ppm (CD
3OD, 400MHz): 0.83 (3H, s, H-19), 1.04 (3H, s, H-21), 1.11 (3H, d, J=6.84Hz, h-27), 3.35 (1H, m, H-6), 3.52 (1H, m, H-3), 3.59 (1H, q).
13The CNMR data see the following form.By above inferred from input data second is peiminine.
Chemical compound third is faint yellow sand crystal, mp246-248 ℃ of .EI-MS m/z:592.2 (M+1)
+, 574.2,458.2,430.2,412.2,394.2,155.1,154.1,112.1 (100%), 98.0,69.0.
1HNMR ﹠amp; Ppm (CD
3OD, 400MHz): 0.86 (3H, s, H-19), 1.13 (3H, d, J=7.6Hz, H-27), 1.16 (3H, s, H-21), 4.39 (1H, d, J=7.62HzH-1 ' H-6).
13The CNMR data see the following form.By above inferred from input data is zhebeinonoside.
The chemical compound fourth is the yellowish white powder, mp246-248 ℃ of .EI-MS m/z:5942 (M+1)
+, 576.2,460.2,432.2,414.2,396.2,155.1,154.1,112.1 (100%), 98.0,69.0.
1HNMR ﹠amp; Ppm (CD
3OD, 400MHz): 0.77 (3H, s, H-19), 1.05 (3H, s, H-21), 1.11 (3H, d, J=6.86Hz, H-27), 4.39 (1H, d, J=7.63Hz, H-1 ').
13The CNMR data see the following form.By above inferred from input data fourth is peiminoside.
The chemical compound first ... fourth
13CNMR chemical displacement value ppm (CD
3OD, 400MHz)
Carbon the first and second the third fourths
1 38.8 39.9 38.0 39.0
2 32.1 32.5 30.6 30.0
3 73.1 73.2 78.8 79.4
4 31.6 33.9 29.7 30.0
5 58.4 54.1 57.4 53.1
6 214.7 71.9 213.8 71.1
7 47.4 42.2 46.6 41.2
8 43.6 40.9 42.7 39.6
9 58.4 59.2 57.5 58.3
10 40.3 37.1 39.6 36.4
11 31.6 31.6 29.9 29.6
12 42.9 43.1 42.0 41.6
13 40.9 40.7 40.0 39.0
14 46.3 46.0 45.4 45.0
15 26.3 26.6 25.5 25.4
16 22.6 22.6 21.8 21.7
17 51.1 51.2 50.2 49.6
18 64.1 64.2 63.2 61.9
19 13.7 14.0 12.9 13.1
20 73.1 73.1 72.3 72.0
21 22.2 22.4 21.4 21.2
22 72.2 71.9 72.2 71.8
23 21.1 21.1 20.2 19.5
24 30.8 31.1 29.1 29.3
25 30.0 30.0 27.5 28.3
26 64.2 64.4 63.2 62.8
27 18.7 18.7 17.8 17.0
1’ 102.3 102.2
2’ 75.1 75.1
3’ 78.1 78.1
4’ 71.7 71.7
5’ 77.9 77.9
6 ' 62.8 62.8 embodiment 2: biological assessment
Mainly sketch the present invention for the reverse effect of tumor multidrug-resistance in the biotic experiment below by above-claimed cpd (being designated hereinafter simply as Compound P M) in vitro tests and bulk testing.
Biotic experiment mainly carries out Evaluation on effect for the lethal effect of multiple sensitivity and multidrug resistance tumor cells to it by Compound P M, and utilizes model of nude mice bearing tumor Compound P M to be carried out the evaluation of its reversing effect.One, materials and methods: 1.1 material 1.1.1 cells and zooblast strain:
K562, HL60, MCF-7, the KB cell, the former three cell is provided by Inst. of Hematology, Chinese Academy of Medical Sciences's medicament chamber, and the latter is provided by Radiation Medical Science Inst., Chinese Academy of Military Medical Science (CN.
The K562/A02 multidrug resistance cell strain is with P
GpAlbumen raises and is main resistance mechanism.Induce and provide by Inst. of Hematology, Chinese Academy of Medical Sciences's medicament chamber.To 40 times of amycin drug resistances, to harringtonine, vincristine, VP16, crossing drug resistants such as daunorubicin.
MCF-7/Adr: the anti-cell strain of multiple medicines, with P
GpProtein expression raises to main resistance mechanism, is drawn from institute of oncology, Beijing by Inst. of Hematology, Chinese Academy of Medical Sciences's medicament chamber, and provides the author to use.To 100 times of amycin drug resistances, to harringtonine, vincristine, VP16, crossing drug resistants such as daunorubicin.
The HL60/Adr multidrug resistance cell strain, expressing rising with multidrug-associated protein (MRP) is main resistance mechanism.Draw from Japan's cell bank and provide the author to use by Inst. of Hematology, Chinese Academy of Medical Sciences's medicament chamber.To 100 times of amycin drug resistances, to homoharringtonine, mitoxantrone, daunorubicin, crossing drug resistants such as methotrexate.
KB
V200Multidrug resistance cell strain is with P
GpProtein expression raises and is main resistance mechanism.Draw from institute of Materia Medica,Chinese Academy of Medical Sciences and provide the author to use by Radiation Medical Science Inst., Chinese Academy of Military Medical Science (CN, to 175 times of vincristine drug resistances, to amycin, paclitaxel, Colchicine crossing drug resistant.Animal: the Balb/C nude mice, in 4-6 week, female, body weight 16 ± 2 grams are available from the military medicine science
Institute's Experimental Animal Center;
Kunming mouse, in 6-8 week, female, male, 20 ± 2 grams are available from Military Medical Science Institute
Experimental Animal Center.1.1.2 reagent
Compound P M solution: after adding a small amount of distilled water among the Compound P M, splash into 1NHCl and make molten (PH～2), add distilled water to 200 μ g/ml again, be mixed with working solution with the RPMI1640 culture fluid again as mother solution.
The amycin standard substance, the ministry of Health of China medicine is identified institute
The vincristine Experimental Pharmaceutical Factory of Beijing Medical Univ
RPMI1640 culture medium U.S. SIGMA company
Calf serum Military Medical Science Institute
MTT (import) magnificent company packing experimental article and instrument:
Culture bottle
Culture plate
CO2 gas incubator
Microplate reader
Chromatograph of liquid 1.2 experimental techniques: the drug resistance multiple of each persister cell to amycin or vincristine measured in 1.2.1 cell killing enhanced sensitivity test (1); (2) measure Compound P M for each cell strain toxicity, select earlier to be lower than 10% (IC for inhibitory rate of cell growth
50) concentration do enhanced sensitivity test.Sensitization (4) the test operation step of Compound P M when (3) measuring Compound P M and amycin or vincristine use in conjunction:
The trophophase liquid culture cell of taking the logarithm is made into cell suspension with the RPM1640 culture fluid that contains 10% calf serum, and every hole 180 μ l (cytotoxicity test) or 160 μ l (enhanced sensitivity test) add to 96 hole plastic culture plates, and making every porocyte number is 2 * 10
4Individual, cell adapts to growth 12 hours in culture plate, and grouping adds each 20 μ l of experiment medicine, establishes serum-free medium zeroing hole and not dosing cell blank matched group, establishes three parallel holes for every group, and every hole final volume is 200 μ l, and insufficient section is supplied with drug solvent.Put in the CO2 gas incubator, 37 ℃, saturated humidity, 5%CO
2Cultivation is 68 hours under the condition, and every hole adds 5mg/ml MTT liquid 20 μ l, and the same terms was cultivated 4 hours, removed supernatant, and every hole adds dimethyl sulfoxide (DMSO) 150 μ l, the micro oscillator vibration, and abundant dissolved substance, microplate reader detects 540nM wavelength OD value.(5) computational methods inhibitory rate of cell growth
IC
50=suppression ratio is 50% o'clock a drug level
1.2.2 the inoculation of mouse tumor treatment enhanced sensitivity test (1) tumor cell: trophophase multidrug resistance cell strain KB takes the logarithm
V200Cell suspension 1.5 * 10
7It is subcutaneous that/ml, 0.2ml are inoculated in the nude mice back.(2) inoculation KB
V200(the 6th day) is grouped into matched group to cell after five days, lumbar injection vincristine 0.4 μ g/ Mus/sky is organized, or vincristine 0.4 μ g/ Mus/sky 5 usefulness Compound P M30 μ g/ Mus/sky group.Had a rest two as a course of treatment, continue a course of treatment in 5th.(3) measure the sensitization of Compound P M, treating lives after two courses of treatment immediately kills mice, claims the tumor body weight, as evaluation index.1.2.3 the pharmacokinetics of Compound P M test (1) Compound P M solution 30 μ g/0.2ml intraperitoneal injection of mice (1.5mg/kg body weight), different time is lived and is got blood and liver, spleen, lung and cerebral tissue extremely.(2) Compound P M amount in high effective liquid chromatography for measuring different time blood plasma and the tissue.Two, result 2.1 K562/A02, MCF-7/Adr, HL60/Adr, KB
V200Cell strain drug resistance multiple is measured cell strain amycin IC
50Vincristine IC
50The drug resistance multiple
(μ g/ml) be K562 0.45 ± 0.051K562/A02 17.56 ± 1.823 39MCF-7 0.06 ± 0.007MCF-7/Adr 8.96 ± 0.986 1,40H,L60 0.08 ± 0.009HL60/Adr 8.16 ± 1.027 102KB 6.7 ± 0.7KB (ng/ml)
V2001297.6 the cytotoxic assay of ± 0.33 193 Compound P M: cell line Compound P MIC
50IC
10
(μg/ml) (μg/ml)K562 328.50±36.52 65.35±7.58K562/A02 300.06±33.18 60.63±7.34MCF-7 438.03±38.56 97.20±11.2MCF-7/Adr 412.02±45.40 83.16±9.35HL60 288.27±34.23 66.29±8.10HL60/Adr 256.52±26.15 58.08±6.02KB 104.32±34.96 21.51±10.29KB
V200 130.69±24.56 46.30±12.67
Compound P M kills and wounds the sensitization of drug-resistant tumor cell to amycin.By inhibitory rate of cell growth is the 50% enhanced sensitivity multiple that calculates: cell line AdrIC
50Adr+PMIC
50The enhanced sensitivity multiple
(μg/ml) (μg/ml)K562 0.45±0.058 0.31±0.041 1.5K562/A02 17.52±1.932 3.07±0.426 5.7MCF-7 0.06±0.008 0.05±0.006 1.2MCF-7/Adr 8.96±0.974 1.53±0.212 5.9HL60 0.04±0.005 0.04±0.006 1.0HL60/Adr 8.16±9.083 1.45±0.197 5.6
*The final concentration of PM is 50 μ g/ml, N=5
Compound P M kills and wounds the sensitization of drug-resistant tumor cell to vincristine (Vin).By inhibitory rate of cell growth is the 50% enhanced sensitivity multiple that calculates: cell line VinIC
50Vin+PMIC
50The enhanced sensitivity multiple
(ng/ml) (ng/ml) KB 4.87 ± 1.55 1.69 ± 0.63 2.8KB
V2001661.6 ± 552 233.89 ± 65.0 7.9
*The final concentration of PM is 20 μ g/ml N=3
Repeatedly experimental result shows: Compound P M kills and wounds multidrug resistance tumor cells for amycin or vincristine and has tangible sensitization, and promptly PM has tangible reverse effect really for above-mentioned two kinds of drug-fast tumor cells of medicine.It reverses multiple Yue Keda about 5.For inferring the probability of its clinical practice, use again and kill and wound the IC of this multidrug resistance tumor cells when MCF-7/Adr cell line has been tested Compound P M difference dose
50, and calculate the variation that it reverses multiple.Result such as following table:
PM dosage (μ g/ml) reverses multiple
50 5.6
20 3.46
10 1.54
5 1.24
2.5 1.19
0.5 1.20
*Cell strain is MCF-7/Adr
It is better that the result shows that Compound P M kills and wounds the effect of enhanced sensitivity of mdr cell for amycin when high concentration.Along with the decline of compound concentration, this effect also subtracts mistake rapidly.Identical (the Biochem Pharmacology1995 of the trend that this dose-effect relationship changes and other inversion agent such as isoptin, 50 (8): 1245-55), and the latter's still unsure its actual application value in clinical verification, obstacle just is that effect is arranged when drug level is high, but can't reach this level (Chinese Journal of Hematology 1988 in the human body, 9 (6): 340-3) and drug level when low, the cause that effect is too low again.Therefore the effect in the time of if can improving Compound P M low concentration just may have the meaning of practical application.The present invention adopts low dose compounds PM and low dosage isoptin (Ver) 5 usefulness, and to improve the effect of PM to the MCF-7/Adr cell, the result is as follows:
Group reverses multiple
PM(0.5μg/ml) 1.151
Ver(0.5μg/ml) 1.199
PM+Ver 1.540
(0.5μg+0.5μg)
This explanation isoptin can make the PM effect improve.And this result as with preceding table (reversing effect of various dose PM) reference mutually, can roughly estimate the effect when it is equivalent to PM10 μ g/ml, promptly quite PM has improved the effect of twenty times of dosage; Because the dosage of isoptin is very low, this dosage is that human body can tolerate fully.Compound P M 5 usefulness isoptins may have the meaning of practical clinical under this condition.2.2 Compound P M is for the reverse effect in the tumor-bearing mice bulk testing
Experiment is used the Balb/C nude mice, the about 16 ± 2g of body weight, 4-6 week in age.
Subcutaneous vaccination 1.5 * 10
7/ mlKB
V200Grouping on the five behind the cell 0.2ml.Be matched group, vincristine i.p 4 μ g/ Mus/sky group, vincristine i.p 4 μ g/ Mus/skies add PM i.p30 μ g/ Mus/sky group.The medicine injection was a course of treatment in 5 days, had a rest two days.Medication is promptly lived after one course of treatment and is claimed tumor heavy extremely again.The result is as showing:
Group tumor heavy (g)
Contrast 0.846 ± 0.237
Vincristine 0.731 ± 0.400
Vincristine+PM 0.618 ± 0.407
*N＝5
PRELIMINARY RESULTS shows that vincristine can make the tumor bulk-growth slower than matched group person, and vincristine adds PM person's better effects if.2.3 the pharmacokinetics of Compound P M test
Utilize behind the reversed phase liquid chromatography quantitative analysis mice i.p PM 30 μ g/ Mus content of Compound P M in the different time blood plasma and liver, spleen, lung and cerebral tissue.Blood plasma Chinese medicine concentration change sees Table:
Get blood time PM concentration (μ g/ml)
(after the injection) (M ± SD)
5 minutes 0.78 ± 0.190
10 minutes 0.96 ± 0.140
20 minutes 0.79 ± 0.087
30 minutes 0.53 ± 0.008
60 minutes 0.43 ± 0.072
2 hours 0.25 ± 0.035
4 hours 0.11 ± 0.020
8 hours 0.034 ± 0.008
12 hours 0.00
*N＝4
Behind the mouse peritoneal injection Compound P M pharmacokinetic parameter T (1/2) C (Max) T (Peak) AUC CL/F (S) V/F (C) (h) (μ g/ml) (h) after (μ g/ml) h μ g/kg/h (μ g/ml) (μ g/kg/ μ g/ml) 0.84 0.87 0.15 1.60 1265.9 1535.9 each internal organs Chinese medicine concentration change trend but peak value similar substantially to the blood plasma person moves, content is higher in spleen and the lymph node.Discuss:
Along with the mechanism of multidrug resistance problem generation and the further investigation of inversion agent, recognize various kinds of cell component such as P gradually
GpAlbumen, multidrug-associated protein (MRP), lung drug-resistant protein (LRP), glutathione s transferase (GST), the expression of topoisomerase-II (Top-ll) etc. or the variation of function all can cause chemical sproof variation, and (Science 1983,221:1285-88, Cancer Res.1989,49:6634, Cancer Res.1991,51:6592, Cancer 1992,70:764, Anticancer Res.1996,16 (2): 709-14).And inversion agent general action known today is also more single, as isoptin, cyclosporin A etc. for expressing P
GpMultidrug resistance cell effect obviously (Molecular Pharmacology 1995,47:51-56, Anticancer Res.1992,12 (6B): 2127-32).Therefore, the searching effect is more extensive or act on other machine-processed inversion agent and just seem very for important.The inversion agent of finding the new chemical structure will increase this probability.Different steroid alkaloid of the present invention is to belong to the newtype chemical constitution as inversion agent, and can act on two kinds of multidrug resistance cell strains (as MCF-7/Adr and HL60/Adr) that mechanism is different, so is the multidrug-resistance reversal agent that belongs to new class from its chemical constitution and functional characteristics, thereby its potential applicability in clinical practice or may be different with the comparatively single inversion agent of effect.The greatest difficulty that runs into when inversion agent carries out the transition to clinical practice at present is that patient can only tolerate smaller dose, and the haemoconcentration level is very low, and the valid density when testing with isolated cells relatively, and is mutually far short of what is expected.Therefore,, find low concentration still to have the medicine of effect, just be easy to be connected mutually with clinical as in test cell line.The present invention considers that the mechanism of action of Compound P M and other inversion agent such as isoptin is different.So 5 usefulness, to increase effect.This data shows that Compound P M0.5 μ g/ml (is equivalent to IC as a result
101/100) 5 usefulness isoptins, 0.5 μ g/ml (clinical safety consumption) effect is obvious.Because more easily reach this with medicament requirement in clinical patient, thereby actual application prospect is comparatively optimistic.Conclusion: 1. Compound P M when isolated test for multidrug resistance tumor cells strain K562/A02, MCF-7/Adr, HL60/Adr and KB
V200Reverse effect is all arranged, (～IC when big with concentration
10), reversing coefficient and can reach about 5 times, reduction drug level then effect descends rapidly.But PM0.5 μ g/ml (IC
101/100 concentration) act on increase with isoptin 0.5 μ g/ml (clinical safety consumption) 5 times spent, effect during suitable approximately PM10 μ g/ml.At lotus KB
V200The preliminary test of cell nude mice shows that mice two all posterior tuberosities of vincristine 0.4 μ g/ Mus i.p treatment heavily are 87% of contrast, and vincristine 0.4 μ g/ Mus to add Compound P M30 μ g/ Mus i.p therapist be 73%.Compound P M to the toxicity of mice is: oral LD
5011.4mg/kg, lumbar injection LD
506.67mg/kg.10 minutes plasma concentration promptly reach the peak behind the lumbar injection 1.5mg/kg.T
1/2Be 0.84h, C (Max) 0.87 μ g/ml, T (peak) 0.15h, the growth and decline trend of AUC1.60 μ g/ml.h tissue concentration and blood plasma person are identical, and content is higher in spleen and the lymph node.
Claims (5)
1. the different steroid alkaloid derivant that has following structure, or the salt that itself and acid form is used to prepare the tumor multidrug-resistance inversion agent as antitumor drug
Wherein: R
1Can be
Or HR
2Can be
Or=O
2. the described chemical compound of claim 1 is used to prepare the antitumor drug that works by reversal of multidrug resistance of tumor cells, and pharmaceutical excipient or carrier.
3. pharmaceutical composition according to claim 2, wherein said pharmaceutical composition can be made into tablet, capsule, injection or granule dosage form.
4. chemical compound according to claim 1, it is characterized in that also can with other inversion agent 5 usefulness, as isoptin.
5. chemical compound according to claim 1, it is used to prepare the multidrug resistance tumor cells inversion agent with the salt that acid forms, and this acid can comprise hydrochloric acid, bromine hydracid, nitric acid, maleic acid, Palmic acid, succinic acid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN98117402A CN1102047C (en) | 1998-08-19 | 1998-08-19 | Reversing agent for multi-medicine resistance of tumor cells |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN98117402A CN1102047C (en) | 1998-08-19 | 1998-08-19 | Reversing agent for multi-medicine resistance of tumor cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1245057A true CN1245057A (en) | 2000-02-23 |
| CN1102047C CN1102047C (en) | 2003-02-26 |
Family
ID=5225504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN98117402A Expired - Fee Related CN1102047C (en) | 1998-08-19 | 1998-08-19 | Reversing agent for multi-medicine resistance of tumor cells |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1102047C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102327571A (en) * | 2011-09-30 | 2012-01-25 | 四川大学 | New cancer-resisting use of fritillaria cirrhosa total alkaloids and compounds contained in fritillaria cirrhosa total alkaloids |
| CN102600142A (en) * | 2012-02-21 | 2012-07-25 | 新疆维吾尔自治区药物研究所 | New application of peiminine in manufacturing gastric cancer multidrug resistance reversing medicaments |
| CN106474125A (en) * | 2016-12-29 | 2017-03-08 | 新疆维吾尔自治区药物研究所 | Peiminine improves the application of the sensitive drug to chemotherapeutics for the tumor cell as preparation |
| CN110672742A (en) * | 2019-10-09 | 2020-01-10 | 浙江省食品药品检验研究院 | Identification method of thunberg fritillary bulb |
-
1998
- 1998-08-19 CN CN98117402A patent/CN1102047C/en not_active Expired - Fee Related
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102327571A (en) * | 2011-09-30 | 2012-01-25 | 四川大学 | New cancer-resisting use of fritillaria cirrhosa total alkaloids and compounds contained in fritillaria cirrhosa total alkaloids |
| CN102600142A (en) * | 2012-02-21 | 2012-07-25 | 新疆维吾尔自治区药物研究所 | New application of peiminine in manufacturing gastric cancer multidrug resistance reversing medicaments |
| CN102600142B (en) * | 2012-02-21 | 2014-08-20 | 新疆维吾尔自治区药物研究所 | New application of peiminine in manufacturing gastric cancer multidrug resistance reversing medicaments |
| CN106474125A (en) * | 2016-12-29 | 2017-03-08 | 新疆维吾尔自治区药物研究所 | Peiminine improves the application of the sensitive drug to chemotherapeutics for the tumor cell as preparation |
| CN110672742A (en) * | 2019-10-09 | 2020-01-10 | 浙江省食品药品检验研究院 | Identification method of thunberg fritillary bulb |
| CN110672742B (en) * | 2019-10-09 | 2022-07-15 | 浙江省食品药品检验研究院 | Thunberg fritillary bulb identification method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1102047C (en) | 2003-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1679631A (en) | Compositions and uses of et743 for treating cancer | |
| CN1429114A (en) | Combination chemotherapy | |
| Wang et al. | Trichinella spiralis—A potential anti-tumor agent | |
| CN1102047C (en) | Reversing agent for multi-medicine resistance of tumor cells | |
| CN1215070C (en) | New compound with anti-tumor function, its preparing method and use in preparing medicine for curing tumor | |
| Lyu et al. | Engineered extracellular vesicles (EVs): Promising diagnostic/therapeutic tools for pediatric high-grade glioma | |
| CN101028348A (en) | Chinese medicinal capsule, its production and quality controlling method | |
| CN1179726C (en) | Application of naringin in preparing medicine for supporting treatment of SARS | |
| CN1504196A (en) | Use of glycyrrhizin and its derivatives as mcp-1 production inhibitors | |
| CN1948502A (en) | Application of TRPC in screening antitumour medicine and medical use of its inhibitor | |
| CN1197641A (en) | Medicine containing tan matter caesalpinia extract | |
| CN1296089C (en) | Zedoary injection preparation and its preparing method | |
| CN1634097A (en) | Application of C21 steroid glycoside in pharmacy | |
| CN101053587A (en) | Medicinal composition for treating tumor and preparation method and quality control method thereof | |
| CN1211088C (en) | Application of emodin analog EMD-31 for curing tumor | |
| CN1418633A (en) | Anti-cancer assistant medicine contg. 20(S)-protopanaxadiol as effective component, and its application | |
| CN1116040C (en) | Medicinal composition and its antalgic purpose | |
| CN1176677C (en) | Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1241555C (en) | Elemene fatty emulsion injection and preparing method thereof | |
| CN1569868A (en) | Pineapple flavonoid glycoside compound and its use | |
| CN1718578A (en) | Lerivisiticum extract, its preparation method and medicine containing said extract | |
| CN1580043A (en) | Anti malignant tumour southern radix bupleuri extract preparing method | |
| CN1738533A (en) | Methods for inhibiting cancer and scar formation | |
| CN1557313A (en) | Leukemia and myeloma treating plant extract and natural chemical monomer | |
| CN1541669A (en) | Prepared traditional Chinese drug Liangfu drop pills for treating epigastric pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |